Who should pay for the continuity of post-trial health care treatments?

The bioethical debate in the world on who should pay for the continuity of post-trials treatment of patients that have medical indication remains obscure and introduces uncertainties to the patients involved i...

Source: International Journal for Equity in Health - June 3, 2019 Category: International Medicine & Public Health Authors: Roberto Iunes, Manuela Villar Uribe, Janet Bonilla Torres, Marina Morgado Garcia, Juliana Alvares-Teodoro, Francisco de Assis Acurcio and Augusto Afonso Guerra Junior Tags: Research Source Type: research